# Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19

> **NCT04457726** · PHASE1,PHASE2 · UNKNOWN · sponsor: **KK Women's and Children's Hospital** · enrollment: 18 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 Specific T Cells

## Key facts

- **NCT ID:** NCT04457726
- **Lead sponsor:** KK Women's and Children's Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2021-03
- **Final completion:** 2022-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-07-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04457726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04457726, "Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04457726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*